Sigma-Aldrich Corp

Sigma-Aldrich — Investor Day (March 2009)

128 slides from Sigma-Aldrich's investor day presentation, Mar 18, 2009

  1. Slide 1: Sigma-Aldrich Corporation: Creating Differentiation Through Innovation

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation March 2009 Exhibit 99.1

  2. Slide 2: Cautionary Statement

    Cautionary Statement Our presentation today will include forward looking statements about the Company’s future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including expectations for sales and earnings cash flow, debt levels, share repurchases and return

  3. Slide 3: Jai Nagarkatti, President and CEO

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation Jai Nagarkatti, President and Chief Executive Officer Sigma-Aldrich Corporation Creating Differentiation Through Innovation

  4. Slide 4: Our Mission and Agenda

    Our Mission: Accelerating Customers’ Success Through Leadership in Life Science, High Technology and Service Agenda Our presentation will cover – - Overview Creating differentiation through innovation to meet changing customer needs and markets - Financial review and outlook Building on a performanc

  5. Slide 5: Building on a Solid Foundation

    Building on a Solid Foundation Unrivalled Scientific Knowledge Shared Principles & Objectives Proven Track Record Focused on Profitable Growth & Value Creation Creating Differentiation Through Innovation Unrivalled Scientific Knowledge Shared Principles & Objectives Proven Track Record Focused on Pr

  6. Slide 6: igma-aldrich.com SIGMA-ALORI

    == igma-aldrich.com SIGMA-ALORI

  7. Slide 7: Positioned for Sustainable, Profitable Growth

    Positioned for Sustainable, Profitable Growth We are Uniquely Positioned for Value Creation Industry leader in life science and high technology research Top 10 global fine chemical manufacturer Diversified products, geographically balanced customers and end markets History of profitable growth with

  8. Slide 8: Enabling Research Across Multiple Disciplines

    Enabling Research Across Multiple Disciplines EQUIP- MENT BIOCHEMICAL ANALYTICAL ORGANIC Broad Capabilities With Room for Growth SIGMA-ALDRICH LIFE TECHNOLOGIES THERMO-FISHER G.E. HEALTHCARE WACO MILLIPORE QIAGEN BECTON DICKINSON VWR MERCK Lab Equip. Biochem Specialties Anti- bodies Cell Signaling M

  9. Slide 9: Top Supplier in $55B Market

    Top 10 Supplier in $55B Market MANUFACTURING MFG. AND SOURCING A Major and Growing Player in the Large Global Fine Chemical Market SAFC BASF EVONIK DSM LONZA COVIDIEN NPIL ALBEMARLE SIEGFRIED DISHMAN Hitech Biosciences Pharma Supply Solutions

  10. Slide 10: Broadest Range of Capabilities vs. Competitors

    Broadest Range of Capabilities vs. Competitors 25% High Technology 75% Life Science 30% High Technology 70% Life Science Our Products Support Diverse Markets and Applications High Technology Advanced materials, alternative energy, electronic chemicals Life Science Pharmaceutical, diagnostic, biotech

  11. Slide 11: Expanding Product Portfolio

    Greater than 50% Growth in Products Offered Since 2000 Expanding Product Portfolio 70,000 (40,000 manufactured) 15,000 Chemicals Products – 85,000 (# of products) 100,000 (46,000 manufactured) 30,000 Laboratory equipment items Products – 130,000 (# of products)

  12. Slide 12: Moving Toward a Balanced Customer Base

    Moving Toward a Balanced Customer Base Broad & Expanding Customer Base Pharmaceutical, Diagnostics, Biotechnology Companies Chemical & Allied Industrial Companies Customers – 60,000 accounts Total sales $1.1 billion (% of 2000 total sales) 40% 30% 10% 20% Customers – 88,000 accounts Total sales $2.2

  13. Slide 13: A Global Partner for Global Companies

    2008: A Global Partner for Global Companies Offices in 37 countries (% of 2008 total sales) 35% 43% 22% Expanding Global Reach United States CAPLA (Canada, Asia Pacific, Latin America) Offices in 33 countries (% of 2000 total sales) Europe 45% 40% 15%

  14. Slide 14: Delivered on All Initiatives

    Delivered on All Initiatives Goals and Results: 2006-2008 Five Key Initiatives Launched to Drive Growth Building on our customer- centric approach Expanding in faster growing markets Building on Internet superiority Leveraging process improvement Investing in long term growth

  15. Slide 15: Building On Our Customer-Centric Approach

    47% Increase in Accounts Served During the Last Three Years Building On Our Customer-Centric Approach Business unit structure aligned to meet customer needs Account management efforts expanded to serve 28,000 new customers worldwide Sales contacts enhanced to support customers’ requirements

  16. Slide 16: Expanding in Faster-Growing Markets

    On Track to Achieve 25% Revenue from CAPLA by 2010 Expanding in Faster-Growing Markets Initial focus in Brazil, China and India achieved combined growth of 15% Enhanced Latin American go-to-market focus produced >20% growth Increased presence in Asia - Enhanced selling and distribution infrastructur

  17. Slide 17: Building on Internet Superiority

    42% of Research Sales Through E-Commerce Channels & Growing Building on Internet Superiority Expanded business-to-business e-commerce hook-ups - More than a million unique visitors monthly - 700,000 new registrations Added high value contextual search applications - Ingenuity - Your Favorite Gene

  18. Slide 18: Leveraging Process Improvement

    Greater Than $100 Million in Total Savings Delivered in Past 7 Years Leveraging Process Improvement A key activity to support growth and profitability Global Supply Chain (GSC) initiatives to improve procurement, manage inventories and enhance customer service – pre-tax benefit $35 - $45 million per

  19. Slide 19: Investing for Long-Term Growth

    Supplementing Organic Growth Through Multiple Approaches Investing for Long-Term Growth 6 acquisitions & 140 new licensing agreements New partnerships for platform technologies and products - Sangamo BioSciences - Atlas Antibodies Expansions for fine chemicals capabilities - Madison - high potency c

  20. Slide 20: New Activities to Exceed Market Growth

    New Activities to Exceed Market Growth Creating Differentiation Through Innovation Looking Forward: 2009-2011

  21. Slide 21: Build on Successes

    Build on Successes Looking Forward: 2009-2011 Accelerate efforts on 2005 strategic plan initiatives - Streamline the global supply chain - Continue Research Biotech focus - Build on success of SAFC Supply Solutions - Pursue opportunities in faster-growing geographies

  22. Slide 22: Continuous Improvement to Deliver Value

    Continuous Improvement to Deliver Value Looking Forward: 2009-2011 Elevate performance to meet high goals - Further enable web strategies - Refine selection and integration of new technologies

  23. Slide 23: Explore and Test Viable New Options for Profitable Growth

    Explore and Test Viable New Options for Profitable Growth Looking Forward: 2009-2011 Create differentiation through innovation - Add a New Ventures Group - Create novel products, services, technologies and business models - Increase market differentiation with breakthroughs in customer value creatio

  24. Slide 24: Deliver on Our Commitments

    Deliver on Our Commitments Looking Forward: 2009 and Beyond Performance expectations - Double digit sales growth – beyond - Improved margins - Maintain ROE >20%

  25. Slide 25: sigma-aldrich.com SIGMA-ALDRICH

    sigma-aldrich.com SIGMA-ALDRICH

  26. Slide 26: Rakesh Sachdev, Chief Financial Officer

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation Rakesh Sachdev, Vice President & Chief Financial Officer

  27. Slide 27: We Are a High Performance Company

    #39 in sales #1 in margins #2 in return on assets We Are a High Performance Company Sigma-Aldrich is - A Fortune 1,000 company - #882 in sales Of 40 chemical companies

  28. Slide 28: 2008 Financial Highlights

    Record Year for Sales and Earnings 2008 Financial Highlights Sales: $2.2 Billion - 8% reported growth; 5% organic growth EPS-Diluted: $2.65 - 13% growth

  29. Slide 29: 2008 Sales Performance by Business Unit

    Each of Our Customer-Centric Business Units Contributed to Growth 2008 Sales Performance in a Difficult Global Economy 12 Months ended December 31, 2008 REPORTED CURRENCY IMPACT ACQUISITION ADJUSTED (ORGANIC) RESEARCH ESSENTIALS RESEARCH SPECIALTIES RESEARCH BIOTECH RESEARCH CHEMICALS SAFC TOTAL 7.7

  30. Slide 30: All Geographic Regions Grew in 2008

    BRIC Countries Growth Continued in Double-Digits All Geographic Regions Grew in 2008 12 Months ended December 31, 2008 REPORTED CURRENCY IMPACT ACQUISITION ADJUSTED (ORGANIC) U.S. EUROPE CAPLA TOTAL 5.4% -% 0.1% 5.3% 8.6 4.8 0.2 3.6 11.9 3.1 0.3 8.5 7.9% 2.7% 0.2% 5.0%

  31. Slide 31: P&L Highlights - 2008 vs. Prior Year

    Strong Growth in Profits and Margins Year Over Year P&L Highlights - 2008 vs. Prior Year Actual vs. 2007 Sales $2,201 $162 Gross Profit 1,130 % Sales 51.3% 0.5% SG&A (45) R&D (5) Operating Income % Sales 22.9% 0.4% Interest, net (8) Pretax $490 $52 % Sales 22.2% 0.7%

  32. Slide 32: We've Achieved Strong Top Line Growth

    5 Year Sales Growth Exceeded 10% CAGR Target 1,409 1,667 1,798 2,039 2,201 1.5 2.0 2.5 We’ve Achieved Strong Top Line Growth

  33. Slide 33: Managing Margins Through The Growth Period

    19% 28% Strong Operating Margins Held While SAFC Grew, Largely Through Acquisitions While Managing Margins Through The Growth Period 19% 81% 28% 72% 22.6% 22.9% OP Margins $1.4 $2.2 SAFC SAFC RESEARCH RESEARCH RESEARCH

  34. Slide 34: Producing Strong Operating Income Growth

    Since 2004 We’ve Added about $200M in Operating Profits From $800M in Added Revenues Producing Strong Operating Income Growth

  35. Slide 35: Generating Solid Returns for Our Investors

    Strong Operating Performance Combined With Share Repurchases Have Resulted in Steady EPS Growth 1.67 1.88 2.05 2.34 2.65 1.00 2.00 3.00 Generating Solid Returns for Our Investors

  36. Slide 36: Continuing to Generate Strong Free Cash Flow

    In 2008 We Invested in Short-term and Long-term Growth Continuing to Generate Strong Free Cash Flow $ 342 (55) (90) $ 314 Net Income Free Cash Flow Net Cash from Operations Less Capital Expenditures Other Changes in Working Capital* Depreciation & Amortization $ 311 (9) (78) $ 339 *Accounts Receivab

  37. Slide 37: Selected Balance Sheet Data

    Higher Net Debt in 2008 from Share Repurchases Expected to Reduce in 2009 Selected Balance Sheet Data – Strong Position CASH TOTAL DEBT $252M $238M 729M 538M DEBT TO CAPITAL 34.6% 25.0% *Accounts Receivable + Inventory - Payables Year End AVG. WORKING CAPITAL (% OF SALES) 36.7% 37.9% WORKING CAPITAL

  38. Slide 38: We've Consistently Exceeded Our 20% ROE Goal

    ROE Remains One of Our Long-term Management Incentive Metrics We’ve Consistently Exceeded Our 20% ROE Goal Shareholder returns: Repurchased shares for $421 million in 2008 Returned $65 million to shareholders through dividends in 2008 Continue earning trust through our performance

  39. Slide 39: Our Dividend Growth Has Been Consistent

    Fairly Unique in Our Industry 0.34 0.38 0.42 0.46 0.52 0.20 0.30 0.40 0.50 Our Dividend Growth Has Been Consistent Dividends: $65 million in cash dividends for 2008 0.60

  40. Slide 40: Relative Return to Shareholders

    SIAL Exceeded Market Performance Relative Return to Shareholders $100.00 $199.97 $131.86 $106.99 $113.36 $140.88 $156.23 $0.00 $50.00 $100.00 $150.00 $200.00 $250.00 28-Feb SIAL PEER GROUP Nasdaq 100 S&P 500 DJIA

  41. Slide 41: 2009 Outlook: Uncertain Market Conditions

    Uncertain Market Conditions 2009 Outlook Current uncertainty in global markets reduces future visibility Demand from some key markets may decline in 2009 Currency expected to reduce growth by approximately 7% with exchange rates at current levels New program launches, global sales initiatives and ma

  42. Slide 42: Modest Resilience to Recessionary Pressures

    Modest Resilience to Recessionary Pressures 2009 Outlook Product portfolio provides resiliency 70% of business tied to research - Moderate growth in current climate 30% tied to manufacturing - Temporarily challenged Potential to expand margins despite currency headwind - Supply chain improvement ini

  43. Slide 43: SIGMA-ALDRICH

    SIGMA-ALDRICH

  44. Slide 44: Slide 44

  45. Slide 45: Key Financial Metrics for 2009

    Key Financial Metrics for 2009 Sales Growth DRIVERS Life Science & High Technology Markets Emerging Markets E-Commerce Sales New Technologies Operating Income Global Supply Chain Initiative Procurement Initiatives Product Line Analysis Cost Management Strategic Pricing Free Cash Flow Working Capital

  46. Slide 46: Fostering a Performance-Driven Culture

    Sigma-Aldrich Fostering a Performance-Driven Culture Management incentives tied to key financial metrics - Near-term performance Sales growth, operating income, free cash flow, individual goals - Long-term performance Sales growth, ROE Management ownership requirement - ¼ - 3 times annual base salar

  47. Slide 47: Managers are Owners

    Managers are Owners Management Investment Management Share Ownership (12-31-08) SENIOR MGMT. GROUP DIRECTOR/ MGR. GROUP BOARD OF DIRECTORS TOTAL TOTAL SHAREHOLDING REQUIREMENT (MILLIONS) VALUE OF SIGMA-ALDRICH HOLDINGS (MILLIONS) EQUIVALENT NUMBER OF SHARES HELD (THOUSANDS) $2.5 $11.4 $0.6 $24.5 $4.

  48. Slide 48: 2009 Guidance

    Guiding at or Above 2008 Performance Despite Strong Currency Headwind 2009 Guidance Organic Revenue Growth Reported EPS Free Cash Flow Low single digits At or above 2008 > $300M

  49. Slide 49: Investment Thesis

    Well Positioned for the Future Sigma-Aldrich Investment Thesis Robust business model– even in a downturn Demonstrated historical performance Able to fund significant growth

  50. Slide 50: Frank Wicks, Research Essentials & Specialties

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation Frank Wicks, President, Research Essentials & Research Specialties

  51. Slide 51: igma-aldrieh.

    igma-aldrieh.

  52. Slide 52: We are the Leader

    We are the Leader Research Essentials/Specialties Market Overview Market - Size - $5.0 billion - Sigma-Aldrich share – 20-25% Customer requirements - Low transaction costs - Simple and transparent order process - Easy to locate products - Product quality, availability and rapid delivery Competitors

  53. Slide 53: Our Core Business

    Our Core Business Research Essentials/Specialties Business Unit Overviews 110,000 products $1.2 billion in sales Research Essentials – competitive pricing Research Specialties – high margin, largely sold at catalog price Broad customer base - >1 million end users Number one in many markets Catalogs

  54. Slide 54: Quality, Reliability and Service Drives Customer Loyalty

    Quality, Reliability and Service Drives Customer Loyalty Research Essentials/Specialties Mission Essentials - Profitable growth by gaining market share and sustaining margins through account management Specialties - Profitable above market sales growth through innovative new product introduction, se

  55. Slide 55: Strategies for Profitable Growth

    Strategies for Profitable Growth Research Essentials/Specialties Strategy Expand geographically Maximize components of our pricing strategy Target marketing across customers, regions and products Provide innovative new products and differentiated services

  56. Slide 56: Global Footprint - Key Strategic Advantage

    Global Footprint – Key Strategic Advantage Research Essentials/Specialties Translating Strategy into Actions Expand geographically - Expand using virtual subsidiary concept - SAP implementation in South Korea - Expand current distribution capabilities in India and China - Targeted marketing to areas

  57. Slide 57: Taking Advantage of Our Global Customer Contact

    Taking Advantage of Our Global Customer Contact Research Essentials/Specialties Translating Strategy into Actions Targeted marketing and pricing - Maximize strategic pricing in market segments and local markets - Leverage our over 1 million customer contacts through direct mail and email campaigns -

  58. Slide 58: 2.5 Million Catalogs In Circulation

    2.5 Million Catalogs In Circulation; 1 Million Plus Customer List Research Essentials/Specialties Customer Contact Our Firepower: Print Global Coverage 1 M catalogs/year 3 M newsletters, 30 issues/year Hitting the Target >1 M names with up-to-date profiles Directed to specified “communities” Being E

  59. Slide 59: Innovation is a Driver

    Innovation is a Driver Research Essentials/Specialties Translating Strategy into Actions Provide innovation through products and services - Adding over 3,000 new products - Expanding business development activities - Analytical – no “me too” technologies Ascentis Express – new stationary phase HPLC

  60. Slide 60: Delivered Above Target Growth

    Delivered Above Target Growth Research Essentials/Specialties 2008 Results and Outlook RE – 4.9% sales growth (currency adjusted) RS – 6.4% sales growth (currency adjusted) Key Drivers - International expansion – CAPLA 8.5% growth - Price - Targeted marketing - New services and products 2009 revenue

  61. Slide 61: Dave Smoller, Research Biotech

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation Dave Smoller, President, Research Biotech

  62. Slide 62: Innovative Life Science Products

    Innovative Life Science Products Research Biotech Research Specialties 38% ($824M) Research Essentials 19% ($421M) SAFC 28% ($624M) Research Biotech 15% ($332M) Business Units Customer Types Driving Forces Research Essentials Economic Buyers Relationship Selling Research Specialties Lab Scientists T

  63. Slide 63: Continued Investment in Technology

    Continued Investment in Technology Research Biotech Market Overview Market - Size – >$5.0 billion - SIAL share >5% Customer requirements - Technology and solution-oriented products - Data associated with products - Technical sales and support Competitors - GE Healthcare; Life Technologies; Millipore

  64. Slide 64: Continually Expand Technology Portfolio

    Continually Expand Technology Portfolio Over 200 R&D Scientists Research Biotech Business Unit Overview 20,000 products $330 million sales Product innovation and ease of use key E-Knowledge Intellectual property portfolio key R&D capabilities essential Leverage products into new areas of research -

  65. Slide 65: Provide Innovation Solutions

    Provide Innovation Solutions Research Biotech Our Mission A key challenge for researchers is to understand the dynamics of the complex molecular interactions within a cell . Our Mission is to be a leading destination place for life science researchers to access deep biological information and market

  66. Slide 66: Lead with Breakthrough Products

    Lead with Breakthrough Products Research Biotech Strategy Achieve consistent double-digit sales growth Acquire new biologically rich content products Leverage portfolio of biologically rich content products, services and information Enable customers to achieve an even deeper understanding of biology

  67. Slide 67: Market Share Growth and Expansion

    Market Share Growth and Expansion Research Biotech Translating Strategy to Actions Add biologically rich content - Antibodies - RNAi - Zinc Fingers - Small Molecules Leverage that content into premium products and new markets - Immunoassays - Cell based assays - Transgenics

  68. Slide 68: Add Biological Rich Content Products

    Add Biological Rich Content Products Added over 8,000 antibodies in 2008 Added over 3,800 Prestige Antibodies through our exclusive partnership with Atlas Antibodies and the Human Proteome Resource Over 500 experimental images for each Prestige antibody All available through our YFG search engine Re

  69. Slide 69: Biologically Rich Content Products: RNAi/Zinc Fingers

    Research Biotech Increase Biologically Rich Content Products-RNAi/Zinc Fingers RNAi-gene silencing ZFNs-gene editing New Era in Science: understanding gene function requires technology - Understanding the function of genes and other parts of the genome is known as functional genomics - 30,000 genes

  70. Slide 70: Smad3 shRNA

    Smad3 shRNA rescues responses of satellite cells in old niche in vivo! Morgan E. Carlson, et al. NATURE | Vol 454 | 24 July 2008 IHC demonstrating muscle regeneration Control fRFP We can see fluorescence in the lung Research Biotech RNAi In vivo

  71. Slide 71: Targeted and Efficient Genomic Scissors

    Correction, Disruption, Insertion Targeted and Efficient Genomic Scissors Research Biotech Zinc Fingers - Gene Modification Ultimate Gene Silencing

  72. Slide 72: Many Applications in Research

    Many Applications in Research Research Biotech Potential to Expand into Multi-Billion Dollar Markets Protein production HTP screening Stem cells Cell based assays In vitro toxicology Cell Line Engineering ZFNs Animal models of human disease Protein production in animals Toxicology Transgenic Animals

  73. Slide 73: Technology is Here Today

    _____ Technology is Here Today Research Biotech Multiple Gene Knockout in Mammalian Cells Wild type cells GS -/- GS ZFNs WT GS -/- GS GS = glutamine synthetase GS -/- DHFR -/- DHFR ZFNs DHFR GS b-Tubulin 2KO DHFR = dihydrofolate reductase GS -/- DHFR -/- Fut8 -/- Fut8 ZFNs WT, no F-LCA WT, + F-LCA 1

  74. Slide 74: Technology is Here Today

    Technology is Here Today Research Biotech Leverage Zinc Fingers to Understand Regenerative Medicine Targeted Gene Integration (e.g. Zinc Fingers Differentiate Cells)

  75. Slide 75: Drive Awareness of New Products with Scientific Content

    Drive Awareness of New Products with Scientific Content on the Web Research Biotech Knowledge Based Search Improves Customer Experience

  76. Slide 76: Doubled Growth Rate in 2008

    Doubled Growth Rate in 2008 Research Biotech 2008 Results and Outlook 7.0% sales growth (currency adjusted) Key drivers - Strong growth in all product initiatives Cell signaling, functional genomics, proteomics - Slower growth in custom products - Exited custom peptide business - Launched gene editi

  77. Slide 77: Gerrit van den Dool, Sales

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation Gerrit van den Dool, Vice President, Sales

  78. Slide 78: Comprehensive Approach for Our Customers

    Comprehensive Approach for Our Customers Research Sales Research Specialties 38% ($824M) Research Essentials 19% ($421M) SAFC 28% ($624M) Research Biotech 15% ($332M) Business Units Customer Types Driving Forces Research Essentials Economic Buyers Relationship Selling Research Specialties Lab Scient

  79. Slide 79: One Million Individual Customers Worldwide

    One Million Individual Customers Worldwide in Over 88,000 Accounts Research Sales Sales Organization & Approach Printed catalog Internet Telephone selling - Inbound: tech & customer services - Outbound: tele-account management Field sales - Relationship: account management - Consultative: sales spec

  80. Slide 80: Broad and Differentiated Customer Base

    Broad and Differentiated Customer Base Research Sales 2008 Results Pharmaceutical, diagnostics, biotechnology companies - Growth: modest - Drivers: cost savings, outsourcing service solutions Chemical and allied industrial companies - Growth: modest - Drivers: application solutions Academia, non-pro

  81. Slide 81: Leverage Differentiated Selling Approach

    Leverage Differentiated Selling Approach Research Sales Goals and Initiatives Accelerate – Elevate – Innovate Sales and marketing alignment - Integration with BU marketing Increase number of customer contacts - Increase telephone activity - Sales analytics Price effectiveness Drive e-solutions and i

  82. Slide 82: Gilles Cottier, President, SAFC

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation Gilles Cottier, President, SAFC

  83. Slide 83: Innovative Solutions For Commercial Customers

    Innovative Solutions For Commercial Customers SAFC Business Units Customer Types Driving Forces Research Essentials Economic Buyers Relationship Selling Research Specialties Lab Scientists Transactional Selling Research Biotechnology Life Scientists Innovation SAFC Project & Development Managers Cus

  84. Slide 84: Changing Market Conditions Provide Opportunities and Challenges

    Changing Market Conditions Provide Opportunities and Challenges SAFC Fine Chemical Market Overview Market - Size – $55 billion - SIAL – Top 10 player Customer requirements - Products from stock: quality, availability, price - Made-to-order: on-time, on quantity, on quality, solution provider - Vendo

  85. Slide 85: SAFC Revenue Tripled to $600M in Five Years

    1990 2000 2004 2005 2006 2007 2008 Fine Chemicals Division Organized Operational Improvements 2005 Strategic Plan JRH & Proligo Acquired Ultrafine & Tetrionics Acquired Iropharm & Pharmorphix Acquired Epichem & MMB Acquired SAFC Revenue Tripled to $600M in Five Years SAFC Business Unit Overview Fine

  86. Slide 86: Pipeline Getting Stronger

    Pipeline Getting Stronger SAFC Project Pipeline Pharmaceuticals and Biopharmaceuticals

  87. Slide 87: A Trusted Partner with Complete Transparency

    A Trusted Partner with Complete Transparency SAFC Distinct Advantages Over Competitors A financially robust partner Well-established breadth of capabilities - Increasingly important Beyond acting “just” as a CMO Security of supply chain Quality solutions for evolving industry needs Global infrastruc

  88. Slide 88: World Class Chemistry and Biochemistry Support

    World Class Chemistry and Biochemistry Support for Development Through Commercial Phases 18% 25% 46% 11% SAFC Value Drivers SAFC Pharma - Complex custom development & manufacturing - Small molecule API and biologics - Technical expertise - Industry-leading project management SAFC Biosciences - Criti

  89. Slide 89: Gain Market Share in High Growth Segments

    Gain Market Share in High Growth Segments by Exceeding Customer Expectations SAFC Mission - Firmly establish our position as a top 10 player in the fine chemicals market while enhancing returns Strategy - Take complete SAFC capabilities offering to large life science customers - Leverage our quality

  90. Slide 90: World's Largest Media Supplier

    World’s Largest Media Supplier SAFC Biosciences Growth Opportunities and Tactics Focus on supplying cell culture-based critical raw materials - Increase customer intimacy - Capture more early-stage clinical projects to feed late-stage potential - Capitalize on disposable solution product breadth - D

  91. Slide 91: Technical Expertise in Complex Custom Development

    Technical Expertise in Complex Custom Development and Manufacturing SAFC Pharma Growth Opportunities and Tactics Focus on complex and niche technologies - High-potent APIs and bioconjugation - Viral drug products - Animal- or plant-sourced APIs - Bacterial and fungal fermentation - Solid-state chemi

  92. Slide 92: Customized and Flexible Service

    Customized and Flexible Service SAFC Supply Solutions Growth Opportunities and Tactics Target market segments with enhanced quality and customized solutions - New customer segment offers - Supply chain enhancements - Enhanced quality profile - Pricing effectiveness - Resource and train personnel in

  93. Slide 93: Collaborative Research Expertise

    Collaborative Research Expertise SAFC Hitech Growth Opportunities and Tactics Focus on collaborative chemistry services enabling future technology for performance materials - Compound semiconductor markets - Silicon semiconductors - Large-area displays - Photovoltaics - Nanotechnology

  94. Slide 94: Deteriorating Market Conditions Toward Year-End 2008

    Deteriorating Market Conditions Toward Year-End 2008 SAFC 2008 Results 3.2% Sales Growth (currency adjusted) Key drivers - Continued strong performance of Supply Solutions - Weakness in European Pharma segment - Double-digit growth in Hitech segment - Performance improving in Biosciences segment

  95. Slide 95: Seize Opportunities in the Economic Uncertainty

    Seize Opportunities in the Economic Uncertainty SAFC 2009 Goals and Initiatives Sales Growth Expectation: Low Single Digits Accelerate - Build on success of SAFC Supply Solutions - Continue investment in growth areas HPAPI, viral particles Elevate - Intensify improvement efforts on SAFC margin to in

  96. Slide 96: David Julien, President, Supply Chain

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation David Julien, President, Supply Chain

  97. Slide 97: An Integrated Effort

    An Integrated Effort Global Supply Chain 2009 & Beyond Planning Centers of Excellence Logistics Quality Control Manufacturing Product Portfolio Management Packaging Procurement

  98. Slide 98: Global Supply Chain Project Goals

    Just starting down the road! Themes are the Same Global Integration - Organization - Supply chain governance - Metrics - Systems (SAP) People - New capabilities & expertise Processes - Complexity reduction - Flexibility - Risk reduction REDUCED COSTS REDUCED WORKING CAPITAL IMPROVED SERVICE SUPPORT

  99. Slide 99: We are Ahead of Schedule

    We are Ahead of Schedule Global Supply Chain Progress 2008 Procurement and planning - Global organization Manufacturing, QC and packaging - Harmonizing, global teams Product portfolio - Eliminating overlaps Logistics and freight - Global management Systems and harmonization - Projects established St

  100. Slide 100: Global Supply Chain Process Improvement

    Global Supply Chain Process Improvement 2008 RESULTS Inventory management 7.3 to 7.0 months on hand Supply chain savings $7 million Process improvement savings $15 million Service rates improved slightly over 2007 Safety improved over 2007 2009 TARGETS Inventory management <7.0 months on hand Supply

  101. Slide 101: Achieve Short- and Long-Term Benefits

    Achieve Short- and Long-Term Benefits Global Supply Chain 2009 Efforts Accelerate - Procurement - Planning Elevate - Product portfolio optimization - Centers of excellence Innovate - Customer solutions

  102. Slide 102: Continue 2008 Success

    Continue 2008 Success Global Supply Chain Accelerate Procurement Review Centralizing under one global organization Increasing savings target by $10 million total Increasing target on recurring direct and indirect costs by $5M Adding professional headcount Spend analysis tool for indirects 10% of ind

  103. Slide 103: Reduced Inventory by $35 Million While Improving Fill Rates

    Reduced Inventory by $35 Million While Improving Fill Rates Global Supply Chain Accelerate Planning Centralizing planning function Refining inventory approval process Reducing cycle time Pulling forward projects into 2009 from 2010/2011 US / Europe Fill Rate 94.0% 94.5% 95.0% 95.5% 96.0% 28,000 addi

  104. Slide 104: Product Optimization Expected to Reduce Complexity

    Product Optimization Expected to Reduce Supply Chain Complexity Global Supply Chain Elevate Product Portfolio Management 2007-8 Product and SKU Consolidation- complete - 20,000 duplicate products eliminated 2007-9 Decoupling- ongoing - Closer to source and/or customer 2008-9 Slow Seller Management-

  105. Slide 105: Right Place and Right Time

    Right Place and Right Time Global Supply Chain Elevate Centers of Excellence Specialized manufacturing, packaging and QC locations Regional centers, minimize freight Procure and package closer to customer Improve cycle time Eliminate redundancy

  106. Slide 106: Moving Up the Value Chain

    Moving Up the Value Chain Global Supply Chain Innovate Customer Solutions Custom packaging/product configuration Customized testing Customer inventory management Chemical procurement services Specialized shipments

  107. Slide 107: Savings and EPS Benefits

    Global Supply Chain Savings and EPS Benefits Expected Savings $15-20 $20-$25 $25-$35 $35-$45 ($millions, pretax) EPS Benefit >$.08-$.11 $.11-$.14 $.14-$.19 $.19-$.24

  108. Slide 108: Carl Turza, Chief Information Officer

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation Carl Turza, Chief Information Officer

  109. Slide 109: E-Commerce: Expect 50% of Research Sales by 2012

    E-Commerce: Expect 50% of Research Sales by 2012 E-Commerce – Strong Growth $550M eSales 2007 $650M eSales 2008 System-to-system (B2B) sales represent 34% of e-Sales More new B2B connections: 2008: +69% New Websphere platform and Sterling Commerce adaptors = faster B2B implementations = % Research S

  110. Slide 110: Further Enable Web Strategies

    Further Enable Web Strategies E-Commerce – Key Messages Drive dynamic publishing Enhance customer experience Redefine search

  111. Slide 111: Continuous Transition From Print Catalogs to Electronic Media

    Continuous Transition From Print Catalogs to Electronic Media Why Dynamic Publishing is Important Growing Content Complexity ~130,000 Active products ~810,000 Product attributes Different catalogs ~130,000 Unique print catalog pages generated in 2008 ~350,000 Unique web catalog pages generated weekl

  112. Slide 112: Remain a True Partner with Our Customers

    Remain a True Partner with Our Customers Enhancing the Customer Experience Enable “mass customization” Website improvements Improve message/marketing relevancy

  113. Slide 113: Make Navigation Intuitive

    Make Navigation Intuitive Website Improvements • Uniform Layout • Clean, Contemporary Design • Localized Merchandising • Simple, One - Box Search • Multi - Language Support • Enable Content Discovery

  114. Slide 114: Unified Messages to Drive Revenue

    Unified Messages to Drive Revenue Marketing Relevancy Equals Growth Unifying Efforts Across the Company 23M Page Views/Month In ‘08, Up 12.5% New B2B Connections Up 69% in ‘08 29M Visits ’08, Up 26% Online Sales $650M, Up 18% in ‘08 Repeat Visits To Our Site Up 17% in ‘08 Attraction Interaction Conv

  115. Slide 115: Context Focused Search Tools

    Context Focused Search Tools Procurement Official Researcher Personal Driven Search Experience

  116. Slide 116: Engage Researchers During The Experimental Design Stage

    Engage Researchers During The Experimental Design Stage Redefining Search It’s search It’s specify It’s discover …within a unified experience

  117. Slide 117: New Contextual Search Capabilities

    New Contextual Search Capabilities Discover Context Around Products Your Favorite Gene Analytical Applications Chemical Reactions

  118. Slide 118: Karen Miller, Strategy and Corporate Development

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation Karen Miller, Vice President, Strategy and Corporate Development

  119. Slide 119: Building a Capability for Breakthrough Innovation

    Building a Capability for Breakthrough Innovation Develop Innovative Solutions that Meet Changing Needs Sigma-Aldrich Corporation New Ventures Group

  120. Slide 120: Accelerating Customers' Success Through Innovation

    Accelerating Customers’ Success Through Innovation Competitive Differentiation Through Innovation Customer Value Creation Sigma-Aldrich innovation requires creation of the capability to identify, evaluate and bring new business ventures to market While difficult times lie ahead, this is the right ti

  121. Slide 121: New Ventures Group is Not a Venture Capital Fund

    New Ventures Group is Not a Venture Capital Fund How Will We Do This? New Ventures Group Objective of New Ventures Group - Build new businesses, from ideas to commercialization - Leverage core competencies - Meet the needs of new and rapidly developing markets - Foster innovation across business uni

  122. Slide 122: How Will The New Ventures Group Be Structured?

    Idea Collection Problem Definition Solutions Business Plans Incubation Launch Defining a New Growth Trajectory How Will The New Ventures Group Be Structured? Collect ideas from customers, suppliers, employees and partners Develop business solutions that solve customer problems Small scale testing an

  123. Slide 123: Expect a Modest Contribution to Sales in 2009

    Expect a Modest Contribution to Sales in 2009 New Ventures Group Activities in Process Building the team… - …all with advanced degrees (PhD’s, MS, MBA’s) - …experienced business people with strong technical skills Building a collaborator network… - …leveraging best practices from industry and academ

  124. Slide 124: Leveraging Scientific and Operational Capabilities

    Leveraging Scientific and Operational Capabilities for New Business Offerings New Ventures Group Activities in Process Incubating two business ideas… - …leveraging product configuration with operational excellence to meet customer need for speed and sustainability - …leveraging sourcing with new e-c

  125. Slide 125: Summary

    Sigma-Aldrich Corporation Creating Differentiation Through Innovation Summary

  126. Slide 126: Accelerating Innovative Leadership in Life Science, High Technology and Service

    Accelerating Innovative Leadership in Life Science, High Technology and Service Sigma-Aldrich Outlook Short-term - Deliver sales and profits - Focus on long-term growth and return Long-term - Double-digit sales growth - Improved margins - ROE >20%

  127. Slide 127: Strategically Positioned for Sustainable Growth

    Strategically Positioned for Sustainable Growth Sigma-Aldrich – An Attractive Investment Our opportunities - Markets large and growing - Global reach and resources - Unrivalled scientific knowledge - World class distribution and logistics - Specialized manufacturing capabilities - Ability to offer c

  128. Slide 128: Questions?

    Questions? Sigma-Aldrich Corporation Creating Differentiation Through Innovation Questions? To ask a question, call the conference telephone number. Toll free: 877-660-8922 • Access Code: 4999095

Sigma-Aldrich — Investor Day (March 2009) on 6ix